Revenue of 5.5 Billion USD, Epilepsy Drugs Market is expected to show enormous growth over forecast period

The research report Epilepsy Drugs Market examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilepsy Drugs Market.

The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market

Get free sample copy of report: https://www.qurateresearch.com/report/sample/HnM/QBI-DPI-HnM-3124

Key Topics Covered:

• Worldwide Epilepsy Drugs Market Analysis (2013 – 2021)
• Worldwide Epilepsy Drugs Market Share (2013 – 2021)
• Worldwide Epilepsy Drugs Brand Market Performance (2013 – 2021)
• Epilepsy Drugs Market – Major Deal Types
• Key Companies Analysis
• Key Drivers and Inhibitors of the Epilepsy Drugs Market

Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle-income countries, are likely to restrict the market growth.

Do you have any questions? Let us know: https://www.qurateresearch.com/report/enquiry/HnM/QBI-DPI-HnM-3124/

Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year end of 2021.

Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.

Key Epilepsy Drugs Covered in the Report are as follows:

1. Vimpat(Lacosamide)
2. Keppra(Levetiracetam)
3. Briviact(Brivaracetam)
4. Lamictal(Lamotrigine)
5. Neurontin (Gabapentin)
6. Depakine (Sodium Valproate)
7. Sabril (Vigabatrin)
8. Onfi(Clobazam)
9. Fycompa(Perampanel)
10. Inovelon/Banzel(Rufinamide)
11. Zonegran (Zonisamide)
12. Zebinix (Eslicarbazepine Acetate)

Key Companies Covered in the Report are as follows:

1. UCB
2. EISAI
3. Pfizer
4. Sanofi
5. Lundbeck

Enquiry of customized report: https://www.qurateresearch.com/report/customize/HnM/QBI-DPI-HnM-3124

Qurate Business Intelligence delivers unique market research solutions to its customers and helps them to get equipped with refined information and market insights derived from reports. We are committed to providing the best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Nehal Chinoy
Runwal Platinum,
Ramnagar Colony, Bavdhan,
Pune, Maharashtra, India-411021
https://www.qurateresearch.com/
IN +919881074592
info@qurateresearch.com

This release was published on openPR.